SlideShare ist ein Scribd-Unternehmen logo
1 von 30
ASTHMA/ COPD
CASE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ,[object Object],[object Object]
[object Object],[object Object],[object Object]
 
COPD stage Severity  Classification by postbronchodilator spirometric values Classification by symptoms and disability I Mild FEV1/FVC < 0.70 FEV1 > 80% predicted Chronic cough + sputum production II Moderate  FEV1/FVC < 0.70 50% ≤ FEV1 < 80% predicted Shortness of breath on exertion III Severe FEV1/FVC < 0.70 30% ≤ FEV1 < 50% predicted Greater SOB, reduce exercise capacity, repeated exacerbation which have impaired on patient’s quality of life IV Very severe FEV1/FVC < 0.70 FEV1 < 30% predicted or FEV1 < 50% predicted plus chronic respiratory failure Chronic respi failure Quality of life very appreciably impaired and exacerbation maybe life threatening.
Management of AECOPD ,[object Object],[object Object],[object Object],[object Object]
 
 
Management of Stable COPD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
β 2 - agonist ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Side effect ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ANTICHOLINERGIC/ANTIMUSCARINIC ,[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
Side effect ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Methylxanthines  ,[object Object],[object Object],[object Object]
Side effects ,[object Object],[object Object]
MOA ,[object Object],[object Object]
 
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Copd Management
Copd ManagementCopd Management
Copd Management
 
asthma management
asthma managementasthma management
asthma management
 
Pharmacotherapy of bronchial asthma
Pharmacotherapy of bronchial asthmaPharmacotherapy of bronchial asthma
Pharmacotherapy of bronchial asthma
 
Management of asthma and copd
Management  of  asthma and copdManagement  of  asthma and copd
Management of asthma and copd
 
pharmacology of asthma
pharmacology of asthmapharmacology of asthma
pharmacology of asthma
 
Antiasthmatics - drdhriti
Antiasthmatics - drdhritiAntiasthmatics - drdhriti
Antiasthmatics - drdhriti
 
Bronchial ashtma Drugs by Dr Harikrishna
Bronchial ashtma Drugs by Dr HarikrishnaBronchial ashtma Drugs by Dr Harikrishna
Bronchial ashtma Drugs by Dr Harikrishna
 
Pharmacotherapy of asthma
Pharmacotherapy of asthmaPharmacotherapy of asthma
Pharmacotherapy of asthma
 
Respiratory drugs
Respiratory drugsRespiratory drugs
Respiratory drugs
 
Drugs acting on respiratory system
Drugs acting on respiratory systemDrugs acting on respiratory system
Drugs acting on respiratory system
 
Brochial asthma drugs
Brochial asthma drugs Brochial asthma drugs
Brochial asthma drugs
 
Drugs used in asthma
Drugs used in asthmaDrugs used in asthma
Drugs used in asthma
 
Bronchodilators and anti inflammatories
Bronchodilators and anti inflammatoriesBronchodilators and anti inflammatories
Bronchodilators and anti inflammatories
 
Pharmacotherapy of Asthma
Pharmacotherapy of AsthmaPharmacotherapy of Asthma
Pharmacotherapy of Asthma
 
Drug therapy for bronchial asthma satya xp
Drug therapy for bronchial  asthma satya xpDrug therapy for bronchial  asthma satya xp
Drug therapy for bronchial asthma satya xp
 
Anti asthmatic drugs ppt
Anti asthmatic drugs pptAnti asthmatic drugs ppt
Anti asthmatic drugs ppt
 
Bronchial asthma
Bronchial asthmaBronchial asthma
Bronchial asthma
 
Pharmacology of asthmatic drugs
Pharmacology of asthmatic drugsPharmacology of asthmatic drugs
Pharmacology of asthmatic drugs
 
Asthma pharmacology and recent advances
Asthma pharmacology and recent advancesAsthma pharmacology and recent advances
Asthma pharmacology and recent advances
 
Asthma presentation and management
Asthma presentation  and managementAsthma presentation  and management
Asthma presentation and management
 

Andere mochten auch (11)

Pharmaco2 asthma
Pharmaco2  asthmaPharmaco2  asthma
Pharmaco2 asthma
 
Heart failure radiology group1 year 5 10-11
Heart failure  radiology group1 year 5 10-11Heart failure  radiology group1 year 5 10-11
Heart failure radiology group1 year 5 10-11
 
Keep Hungry Stay Sexy
Keep Hungry Stay SexyKeep Hungry Stay Sexy
Keep Hungry Stay Sexy
 
8vo curso
8vo curso8vo curso
8vo curso
 
The Art of Execution Management
The Art of Execution ManagementThe Art of Execution Management
The Art of Execution Management
 
Sex Roles & Sub Cultures in Consumer Behavior
Sex Roles & Sub Cultures in Consumer BehaviorSex Roles & Sub Cultures in Consumer Behavior
Sex Roles & Sub Cultures in Consumer Behavior
 
Management of asthma and copd therapeutics yr 5 2010 11a
Management of asthma and copd therapeutics yr 5 2010 11aManagement of asthma and copd therapeutics yr 5 2010 11a
Management of asthma and copd therapeutics yr 5 2010 11a
 
Non cardiogenic pulmonary oedema
Non cardiogenic pulmonary oedemaNon cardiogenic pulmonary oedema
Non cardiogenic pulmonary oedema
 
Final IKEA Case Study
Final IKEA Case StudyFinal IKEA Case Study
Final IKEA Case Study
 
Be Different - Share for YDBA UMKM
Be Different - Share for YDBA UMKMBe Different - Share for YDBA UMKM
Be Different - Share for YDBA UMKM
 
Pulmonary edema & cardiogenic apo
Pulmonary edema & cardiogenic apoPulmonary edema & cardiogenic apo
Pulmonary edema & cardiogenic apo
 

Ähnlich wie Pharmaco 2 copd

Ähnlich wie Pharmaco 2 copd (20)

Asthma
AsthmaAsthma
Asthma
 
Respiratory Drugs
Respiratory DrugsRespiratory Drugs
Respiratory Drugs
 
Respiratory Drugs
Respiratory DrugsRespiratory Drugs
Respiratory Drugs
 
Drugs used in asthma
Drugs used in asthmaDrugs used in asthma
Drugs used in asthma
 
Asthma - Recent advances in treatment
Asthma - Recent advances in treatmentAsthma - Recent advances in treatment
Asthma - Recent advances in treatment
 
Drugs acting on respiratory system
Drugs acting on respiratory systemDrugs acting on respiratory system
Drugs acting on respiratory system
 
ED Management of Asthma
ED Management of AsthmaED Management of Asthma
ED Management of Asthma
 
Pharmacotherapy of asthma
Pharmacotherapy of asthmaPharmacotherapy of asthma
Pharmacotherapy of asthma
 
Respiratory drugs pptx
Respiratory drugs pptxRespiratory drugs pptx
Respiratory drugs pptx
 
Drugs acting on respiratory system
Drugs acting on respiratory system Drugs acting on respiratory system
Drugs acting on respiratory system
 
PHARMACOTHERAPY OF BRONCHIAL ASTHMA
PHARMACOTHERAPY OF BRONCHIAL ASTHMAPHARMACOTHERAPY OF BRONCHIAL ASTHMA
PHARMACOTHERAPY OF BRONCHIAL ASTHMA
 
Bronchodilators
BronchodilatorsBronchodilators
Bronchodilators
 
Bronchodilators
BronchodilatorsBronchodilators
Bronchodilators
 
PHARMACOLOGY I.pptx
PHARMACOLOGY I.pptxPHARMACOLOGY I.pptx
PHARMACOLOGY I.pptx
 
Respiratory Drugs
Respiratory DrugsRespiratory Drugs
Respiratory Drugs
 
LLU Respiratory Pharmacology Review Podcast 2013
LLU Respiratory Pharmacology Review Podcast 2013LLU Respiratory Pharmacology Review Podcast 2013
LLU Respiratory Pharmacology Review Podcast 2013
 
Resp drugs presesntation
Resp drugs presesntationResp drugs presesntation
Resp drugs presesntation
 
INTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.pptINTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.ppt
 
NurseReview.Org - Bronchodilators Updates (ati pharmacology topic descriptors)
NurseReview.Org - Bronchodilators Updates (ati pharmacology topic descriptors)NurseReview.Org - Bronchodilators Updates (ati pharmacology topic descriptors)
NurseReview.Org - Bronchodilators Updates (ati pharmacology topic descriptors)
 
COPD
COPDCOPD
COPD
 

Pharmaco 2 copd

  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.  
  • 8. COPD stage Severity Classification by postbronchodilator spirometric values Classification by symptoms and disability I Mild FEV1/FVC < 0.70 FEV1 > 80% predicted Chronic cough + sputum production II Moderate FEV1/FVC < 0.70 50% ≤ FEV1 < 80% predicted Shortness of breath on exertion III Severe FEV1/FVC < 0.70 30% ≤ FEV1 < 50% predicted Greater SOB, reduce exercise capacity, repeated exacerbation which have impaired on patient’s quality of life IV Very severe FEV1/FVC < 0.70 FEV1 < 30% predicted or FEV1 < 50% predicted plus chronic respiratory failure Chronic respi failure Quality of life very appreciably impaired and exacerbation maybe life threatening.
  • 9.
  • 10.  
  • 11.  
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.  
  • 27.
  • 28.
  • 29.
  • 30.